EYENOVIA Files 8-K for Rule 425 Communications, Nasdaq Listing Confirmed

Ticker: HYPD · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1682639

Eyenovia, INC. 8-K Filing Summary
FieldDetail
CompanyEyenovia, INC. (HYPD)
Form Type8-K
Filed DateJan 25, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.0001, $250 million, $1.8 billion, $2.7 billion, $610 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, securities-act

TL;DR

**EYENOVIA filed an 8-K for Rule 425 communications, signaling potential capital raise or M&A activity.**

AI Summary

EYENOVIA, INC. filed an 8-K on January 25, 2024, primarily to indicate that it is making written communications pursuant to Rule 425 under the Securities Act. This filing also confirms its common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market (Nasdaq Capital Market) under the trading symbol EYEN. This matters to investors because it signals the company is actively engaging in communications related to potential securities offerings or business combinations, which could impact future stock value.

Why It Matters

This filing indicates EYENOVIA is likely communicating about a potential securities offering or business transaction, which could lead to capital raises or strategic changes impacting the stock price.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying 'written communications' could relate to events with significant financial implications, introducing uncertainty.

Analyst Insight

Investors should monitor subsequent filings or press releases from EYENOVIA for specific details about the 'written communications' mentioned, as these could signal significant corporate actions like mergers, acquisitions, or new stock offerings.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of EYENOVIA, INC.'s 8-K filing on January 25, 2024?

The primary purpose of EYENOVIA, INC.'s 8-K filing on January 25, 2024, is to indicate that the filing is intended to simultaneously satisfy the filing obligation of the registrant under 'Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)'.

On which stock exchange is EYENOVIA, INC.'s common stock registered?

EYENOVIA, INC.'s common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market (Nasdaq Capital Market).

What is the trading symbol for EYENOVIA, INC. on the Nasdaq Stock Market?

The trading symbol for EYENOVIA, INC. on The Nasdaq Stock Market is EYEN.

What is the par value of EYENOVIA, INC.'s common stock?

The par value of EYENOVIA, INC.'s common stock is $0.0001 per share.

What is the business address and phone number of EYENOVIA, INC. as stated in the filing?

EYENOVIA, INC.'s business address is 295 Madison Avenue, Suite 2400, New York, NY 10017, and its telephone number is (833) 393-6684.

Filing Stats: 1,144 words · 5 min read · ~4 pages · Grade level 12.3 · Accepted 2024-01-25 07:59:37

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 25, 2024, Eyenovia released an updated investor presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Eyenovia is developing topical ophthalmic medications that utilize its novel, patented Optejet drug-device dispensing platform to address large market indications with significant unmet medical needs. Numerous studies have demonstrated the ability of the Optejet to achieve efficacy with up to 80% less medication than traditional eye drops, resulting in increased local tolerability and decreased systemic exposure to both drug and preservatives. The Optejet technology is protected by a comprehensive IP portfolio, with many claims in effect beyond 2031. Complementing its Optejet device, Eyenovia is developing its Optecare suite of digital applications which leverages the onboard programming and Bluetooth technology in the Optejet to track usage and boost compliance through reminders sent to the patient, which may result in improved patient outcomes. This also represents a potential additional revenue stream for eye doctors under a CPT code for "Remote Therapeutic Monitoring Treatment Management Services." Eyenovia currently has one commercial asset, Mydcombi for mydriasis (in-office and surgical pupil dilation), which is currently being launched commercially. Eyenovia estimates this to be a $250 million market annually, and the updated investor presentation contains several testimonials from early adopters of the technology. Mydcombi represents the first FDA approved drug in the Optejet, providing important validation of the technology. Eyenovia in-licensed its second asset, APP13007 for pain and inflammation following ocular surgery, from Formosa Pharmaceuticals in August of 2023. APP13007 has an FDA PDUFA date of March 4, 2024. APP13007 utilizes Formosa's APNT platform which reduces an active pharmaceutical ingredient's particle si

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d)Exhibits Exhibit No. Description 99.1 Eyenovia, Inc. Updated Corporate Presentation, dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: January 25, 2024 /s/ John Gandolfo John Gandolfo Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing